Vertex Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vertex Pharmaceuticals (VRTX).

Price Target Range — 7 Quarters

Analyst Consensus — 27 Analysts

21Buy

5Hold

1Sell

Consensus RatingBuy# Analysts27Avg. Consensus PT$544Upside to Avg. PT+7.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 28, 2026	UBS	Michael Yee	PT Raise	Buy	$585→$615
Sep 11, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$515→$560
Sep 2, 2026	Morgan Stanley	Terence Flynn	Reinstates	Overweight	$665
Aug 5, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$560→$565
Aug 5, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$615→$617
Aug 4, 2026	TD Cowen	Phil Nadeau	PT Raise	Buy	$525→$550
Aug 4, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$590→$595
Aug 4, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Hold	$436→$442
Jul 13, 2026	UBS	Michael Yee	PT Raise	Buy	$545→$585
Jul 13, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$542→$560
Jul 7, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$543→$570
Jul 7, 2026	Baird	Brian Skorney	PT Raise	Underperform	$330→$350
May 6, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$607→$615
May 5, 2026	Canaccord Genuity	Whitney Ijem	PT Cut	Hold	$437→$436
May 5, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$612→$616
May 5, 2026	Bernstein	William Pickering	PT Cut	Outperform	$577→$572
May 5, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$541→$543
Apr 30, 2026	Canaccord Genuity	Whitney Ijem	PT Cut	Hold	$441→$437
Apr 10, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$596→$612
Mar 18, 2026	Maxim Group	Naz Rahman	Upgrade	Hold→Buy	$575

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615

UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $585 to $615.

Benzinga Newsdesk

Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug

Vertex Pharmaceuticals reported positive Phase 2b data for inaxaplin in patients with APOL1-mediated kidney disease.

Vandana Singh

PRO
Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target

Morgan Stanley analyst Terence Flynn reinstates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and announces $665 price target.

Benzinga Newsdesk

PRO
Live On CNBC, Karen Firestone Announces Bought Vertex Pharmaceuticals

Benzinga Newsdesk

PRO
CNBC Halftime Report Final Trades: ServiceNow, Uber Technologies, Vertex Pharmaceuticals

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565

Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $560 to $565.

Benzinga Newsdesk

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615

Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug

PRO
Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target

PRO
Live On CNBC, Karen Firestone Announces Bought Vertex Pharmaceuticals

PRO
CNBC Halftime Report Final Trades: ServiceNow, Uber Technologies, Vertex Pharmaceuticals

PRO
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565

People Also Watch

People Also Watch

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615

Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug

PROMorgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target

PROLive On CNBC, Karen Firestone Announces Bought Vertex Pharmaceuticals

PROCNBC Halftime Report Final Trades: ServiceNow, Uber Technologies, Vertex Pharmaceuticals

PROTruist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565

People Also Watch

People Also Watch

PRO
UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615

PRO
Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target

PRO
Live On CNBC, Karen Firestone Announces Bought Vertex Pharmaceuticals

PRO
CNBC Halftime Report Final Trades: ServiceNow, Uber Technologies, Vertex Pharmaceuticals

PRO
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565